Literature DB >> 28540933

The effect of high altitude on central blood pressure and arterial stiffness.

C J Boos1,2,3, E Vincent4, A Mellor3,4,5, D R Woods3,4,6,7, C New4, R Cruttenden4, M Barlow3, M Cooke3, K Deighton3, P Scott4, S Clarke3, J O'Hara3.   

Abstract

Central arterial systolic blood pressure (SBP) and arterial stiffness are known to be better predictors of adverse cardiovascular outcomes than brachial SBP. The effect of progressive high altitude (HA) on these parameters has not been examined. Ninety healthy adults were included. Central BP and the augmentation index (AI) were measured at the level of the brachial artery (Uscom BP+ device) at <200 m and at 3619, 4600 and 5140 m. The average age of the subjects (70% men) were 32.2±8.7 years. Compared with central arterial pressures, brachial SBP (+8.1±6.4 mm Hg; P<0.0001) and pulse pressure (+10.9±6.6 mm Hg; P<0.0001) were significantly higher and brachial diastolic BP was lower (-2.8±1.6 mm Hg; P<0.0001). Compared with <200 m, HA led to a significant increase in brachial and central SBP. Central SBP correlated with AI (r=0.50; 95% confidence interval (CI): 0.41-0.58; P<0.0001) and age (r=0.32; 95% CI: 21-0.41; P<0.001). AI positively correlated with age (r=0.39; P<0.001) and inversely with subject height (r=-0.22; P<0.0001), weight (r=-0.19; P=0.006) and heart rate (r=-0.49; P<0.0001). There was no relationship between acute mountain sickness scores (Lake Louis Scoring System (LLS)) and AI or central BP. The independent predictors of central SBP were male sex (coefficient, t=4.7; P<0.0001), age (t=3.6; P=0.004) and AI (t=7.5; P<0.0001; overall r2=0.40; P<0.0001). Subject height (t=2.4; P=0.02), age (7.4; P<0.0001) and heart rate (t=11.4; P<0.0001) were the only independent predictors of AI (overall r2=0.43; P<0.0001). Central BP and AI significantly increase at HA. This rise was influenced by subject-related factors and heart rate but not independently by altitude, LLS or SpO2.

Entities:  

Mesh:

Year:  2017        PMID: 28540933     DOI: 10.1038/jhh.2017.40

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  28 in total

1.  The influence of heart rate on augmentation index and central arterial pressure in humans.

Authors:  I B Wilkinson; H MacCallum; L Flint; J R Cockcroft; D E Newby; D J Webb
Journal:  J Physiol       Date:  2000-05-15       Impact factor: 5.182

2.  Parasympathetic neural activity accounts for the lowering of exercise heart rate at high altitude.

Authors:  R Boushel; J A Calbet; G Rådegran; H Sondergaard; P D Wagner; B Saltin
Journal:  Circulation       Date:  2001-10-09       Impact factor: 29.690

3.  The effects of acute hypobaric hypoxia on arterial stiffness and endothelial function and its relationship to changes in pulmonary artery pressure and left ventricular diastolic function.

Authors:  C J Boos; P Hodkinson; A Mellor; N P Green; D R Woods
Journal:  High Alt Med Biol       Date:  2012-06       Impact factor: 1.981

4.  Expert consensus document on arterial stiffness: methodological issues and clinical applications.

Authors:  Stephane Laurent; John Cockcroft; Luc Van Bortel; Pierre Boutouyrie; Cristina Giannattasio; Daniel Hayoz; Bruno Pannier; Charalambos Vlachopoulos; Ian Wilkinson; Harry Struijker-Boudier
Journal:  Eur Heart J       Date:  2006-09-25       Impact factor: 29.983

5.  The effects of exercise at high altitude on high-sensitivity cardiac troponin release and associated biventricular cardiac function.

Authors:  Christopher John Boos; Adrian Mellor; Joe Begley; Michael Stacey; Chris Smith; Amanda Hawkins; David Richard Woods
Journal:  Clin Res Cardiol       Date:  2013-12-21       Impact factor: 5.460

Review 6.  Should the augmentation index be normalized to heart rate?

Authors:  Lee Stoner; James Faulkner; Andrew Lowe; Danielle M Lambrick; Joanna M Young; Richard Love; David S Rowlands
Journal:  J Atheroscler Thromb       Date:  2013-11-19       Impact factor: 4.928

7.  Influence of body height on pulsatile arterial hemodynamic data.

Authors:  H Smulyan; S J Marchais; B Pannier; A P Guerin; M E Safar; G M London
Journal:  J Am Coll Cardiol       Date:  1998-04       Impact factor: 24.094

8.  Ambulatory blood pressure in untreated and treated hypertensive patients at high altitude: the High Altitude Cardiovascular Research-Andes study.

Authors:  Grzegorz Bilo; Francisco C Villafuerte; Andrea Faini; Cecilia Anza-Ramírez; Miriam Revera; Andrea Giuliano; Sergio Caravita; Francesca Gregorini; Carolina Lombardi; Elisabetta Salvioni; Jose Luis Macarlupu; Deborah Ossoli; Leah Landaveri; Morin Lang; Piergiuseppe Agostoni; José Manuel Sosa; Giuseppe Mancia; Gianfranco Parati
Journal:  Hypertension       Date:  2015-04-20       Impact factor: 10.190

9.  Effects of atropine and propranolol on the respiratory, circulatory, and ECG responses to high altitude in man.

Authors:  E A Koller; S Drechsel; T Hess; P Macherel; U Boutellier
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1988

Review 10.  Central blood pressure: current evidence and clinical importance.

Authors:  Carmel M McEniery; John R Cockcroft; Mary J Roman; Stanley S Franklin; Ian B Wilkinson
Journal:  Eur Heart J       Date:  2014-01-23       Impact factor: 29.983

View more
  3 in total

1.  Compromised mechanical homeostasis in arterial aging and associated cardiovascular consequences.

Authors:  J Ferruzzi; D Madziva; A W Caulk; G Tellides; J D Humphrey
Journal:  Biomech Model Mechanobiol       Date:  2018-05-12

2.  Effect of losartan on performance and physiological responses to exercise at high altitude (5035 m).

Authors:  Samuel J E Lucas; William L Malein; Owen D Thomas; Kimberly M Ashdown; Carla A Rue; Kelsey E Joyce; Charles Newman; Patrick Cadigan; Brian Johnson; Stephen D Myers; Fiona A Myers; Alexander D Wright; John Delamere; Chris H E Imray; Arthur R Bradwell; Mark Edsell
Journal:  BMJ Open Sport Exerc Med       Date:  2021-01-07

3.  Effect of acetazolamide on obstructive sleep apnoea in highlanders: protocol for a randomised, placebo-controlled, double-blinded crossover trial.

Authors:  Lu Tan; Michael Furian; Taomei Li; Xiangdong Tang
Journal:  BMJ Open       Date:  2022-03-07       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.